Intracavernous alprostadil: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction

Drugs and Aging

Volumn 8, Issue 1, 1996, Pages 56-74

  Lea, Andrew P ^a   Bryson, Harriet M ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; DIPYRIDAMOLE; GLYCERYL TRINITRATE; IFENPRODIL; LINSIDOMINE; PAPAVERINE; PHENTOLAMINE; PIRIBEDIL; PROSTAGLANDIN E1; YOHIMBINE;

BLOOD FLOW; CLINICAL TRIAL; CORPUS CAVERNOSUM; DRUG EFFICACY; DRUG MECHANISM; FIBROSIS; HUMAN; IMPOTENCE; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PENIS DISEASE; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; TOPICAL DRUG ADMINISTRATION; VASODILATATION;

EID: 0030053380     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608010-00009     Document Type: Review

References (123)

1. Piper PJ. Distribution and metabolism. In: Cuthbert MF, editor. The prostaglandins. London: Heinemann. 1973: 125-50
2. Templeton AA, Cooper I, Kelly RW. Prostaglandin concentrations in the semen of fertile men. J Reprod Fertil 1978; 52: 147-50
3. 1: a review. Int J Angiol 1994; 3: 160-8
4. Reynolds JEF, editor. Martindale. The extra pharmacopeia. 28th ed. London: Pharmaceutical Press, 1982
5. Lue TF. Impotence after prostatectomy. Urol Clin North Am 1990; 17: 613-20
6. Lue TF, Zeineh SJ, Schmidt RA, et al. Neuroanatomy of penile erection: its relevance to iatrogenic impotence. J Urol 1984; 130: 273-90
7. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989; 321 (24): 1648-59
8. Saenz de Tejada I, Goldstein IJ, Krane RJ. Local control of penile erection: nerves, smooth muscle, and endothelium. Urol Clin North Am 1988; 15: 9-14
9. Miller MAW, Morgan RJ. Review. Eicosanoids, erections and erectile dysfunction. Prostaglandins Leukot Essent Fatty Acids 1994; 51: 1-9
10. Jeremy JY, Morgan RJ, Mikhailidis DP, et al. Prostacyclin synthesis by the corpora cavernosa of the human penis: evidence for muscarinic control and pathological implications. Prostaglandins Leukot Med 1986; 23: 211-6
11. Roy AC, Mian Tan S, Kottegoda SR, et al. Ability of human corpora cavernosa muscle to generate prostaglandins and thromboxanes in vitro. IRCS Med Sci 1984; 12: 608-9
12. van Ahlen H, Peskar BA, Sticht G, et al. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol 1994 May; 151: 1227-30
13. Mikhailidis DP, Jeremy JY. Eicosanoids, impotence and pharmacologically induced erection: a selected symposium overview of the Ist International Symposium on Pharmacological Erection, Paris; 1989 Nov 17. Prostaglandins Leukot Essent Fatty Acids 1990; 40: 239-42
14. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psycholosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
15. Morley JE, Kaiser FE. Impotence in elderly men. Drugs Aging 1992; 2 (4): 330-44
16. Morley JE. Management of impotence. Postgrad Med 1993 Feb 15; 93 (3): 65-72
17. Brock GB, Lue TF. Drug-induced male sexual dysfunction. An update. Drug Saf 1993 Jun; 8: 414-26
18. Whiteman ED, Klyde BJ, Zussman S. Diagnostic evaluation of impotence. Postgrad Med 1990 Aug; 88 (2): 123-36
19. Ackerman MD, Montague DK, Morganstern S. Impotence: help for erectile dysfunction. Patient Care 1994 Mar 15: 22-56
20. Managing impotence in elderly men. Drug Ther Perspect 1993 May 10; 18: 6-9
21. Cohen H, DiGregorio RV. Impotence. US Pharm 1994 Jul: 53-68
22. Kaiser FE, Visoca SP, Morley JE, et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988; 36(6): 511-9
23. NIH Consensus Conference NIH consensus development panel on impotence JAMA 1993; 270: 83-90
24. Hedlund H, Andersson K-E. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985; 134: 1245-50
25. Kirkeby HJ, Andersson K-E, Forman A. Comparison of the effects of prostanoids on human penile circumflex veins and corpus cavernosum tissue. Br J Urol 1993 Aug; 72: 220-5
26. Miller MAW, Morgan RJ, Thompson CS, et al. Adenylate and guanylate cyclase activity in the penis and aorta of the diabetic rat: an in vitro study. Br J Urol 1994; 74: 106-11
27. Rasmussen H. The calcium messenger system. Second of two parts. N Engl J Med 1986; 314: 1164-70
28. Hwang TI-S, Lue TF, Yang CR, et al. Comparison of penile vascular effect induced by intracavernous injection of papaverine and prostaglandin E1. J Formosan Med Assoc 1989 Oct; 88: 1038-41
29. 1 on penile blood flow by color duplex sonography. Eur Urol 1991; 19(1): 49-53
30. Marshall GA, Breza J, Lue TF. Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994 Jun; 43: 844-8
31. Porst H, van Ahlen H, Block TH, et al. Intracavernous self-injection of prostaglandin-E1 in the therapy of erectile dysfunction. Vasa 1989; 28 Suppl.: 50-6
32. Hwang TI, Yang CR, Ho WL, et al. Histopathological change of corpora cavernosa after long-term intracavernous injection. Eur Urol 1991; 20: 301-6
33. 1 and saline in primates. J Urol 1989 Aug; 142: 403-8
34. 2-induced hyperalgesia in the rat. Neuroscience 1994; 62 (2): 345-50
35. Roy AC, Adaikan PG, Ratnam SS. Prostaglandin 15-hydroxy-dehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Br J Urol 1989; 64: 180-2
36. 0 after intracavernous injection in patients with chronic erectile dysfunction [abstract]. J Urol 1995 Apr; 153 Suppl.: 367
37. 1 in man. J Clin Invest 1975; 56: 1404-10
38. 1 in the human pulmonary circulation. Surgery 1977; 81 (6): 716-22
39. 1 in man. Biochim Biophys Acta 1983; 750: 231-6
40. Caverject product monograph. Upjohn Ltd., Crawley, West Sussex, UK. Jan 1994
41. 1 in erectile dysfunction. Clin Investig 1994 Jan; 72: 139-49
42. Linet OI. Clinical pharmacology of alprostadil. In: Goldslein I, Lue TF, editors. The role of alprostadil in the diagnosis and treatment of erectile dysfunction. Princeton: Excerpta Medica, 1993: 28-39
43. Vanderschueren D, Heyrman RM, Keogh EJ, et al. A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Urology 1995 Nov; 154: 1744-7
44. 1 in erectile dysfunction. Br J Clin Pharmacol 1989 Nov; 28: 567-71
45. Chen J, Godschalk M, Katz PG, et al. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction. J Urol 1995 Jan; 153: 80-1
46. Spilker B. Guide to clinical trials. New York: Raven Press, 1991
47. 1 as treatment for erectile failure in elderly men. J Am Geriatr Soc 1994 Dec; 42: 1263-5
48. 1) - comprehensive review. Data on file. Upjohn, Kalamazoo, Michigan, USA. 1995
49. Colli E, Calabrò A, Gentile V, et al. Multicenter study on the use of intracavernous Alprostadil Sterile Powder in the treatment of erectile dysfunction [in Italian]. G Ital Androl 1994; 1(1): 75-7
50. Godschalk MF, Chen J, Katz PG, et al. Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-cotrolled, dose-response study. J Urol 1994 Jun; 151: 1530-2
51. von Heyden B, Donatucci CF, Marshall GA, et al. A prostaglandin E1 dose-response study in man. J Urol 1993 Dec; 150: 1825-8
52. Beretta G, Zanollo A, Portalupi W. Intracavernous injections of prostaglandin E1 in the treatment of erection disorders [in Italian]. Arch Ital Urol Nefrol Androl 1991 Dec; 63: 481-5
53. Calabrò A, Marin A, Todeschini M, et al. Efficacy and tolerability of PGE1 in the treatment of erectile dysfunction [in Italian]. G Ital Androl 1994; 1 (1): 78-80
54. Desvaux P, Mimoun S. Prostaglandin E1 for the treatment of impotence. Efficacy and tolerance as a function of aetiology [in French]. J d'Urol 1994; 100 (1): 17-22
55. Porst H. Prostaglandin E1 in male impotence - its diagnostic and therapeutic use in 2000 patients [abstract]. Int J Impot Res 1992; 4 Suppl. 2: A88
56. Stackl W, Hasun R. Prostaglandin E1 - 4 years experience of intracavernous injections. Int J Impot Res 1990; 2 Suppl. 2: 255-6
57. Earle CM, Keogh EJ, Wisniewski ZS, et al. Prostaglandin E1 therapy for impotence, comparison with papaverine. J Urol 1990 Jan; 143: 57-9
58. Kattan S, Collins JP, Mohr D. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence. Urology 1991 Jun; 37: 516-8
59. Mahmoud KZ, El Dakhli MR, Fahmi IM, et al. Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients. J Urol 1992 Mar; 147: 623-6
60. Sarosdy MF, Hudnall CH, Erickson DR, et al. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence. Urology 1989; 141 (3): 551-3
61. Lee LM, Stevenson RW, Szasz G. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 1989 Mar; 141: 549-50
62. 1. Int J Impot Res 1990; 2 Suppl. 1: 147-57
63. Roy JB, Petrone RL, Ibrahin T. A clinical trial of the intracorporal injection of papaverine/phentolamine vs PGE1 vs topical nitroglycerin ointment in the treatment of erectile dysfunction. Int J Impot Res 1990; 2 Suppl. 2: 305-6
64. Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988 Sep; 140: 525-7
65. 1 versus linsidomine chlorhydrate in erectile dysfunction. Urol Int 1994; 53: 214-6
66. Andersson K-E. Pharmacology of erection: agents which initiate and terminate erection. Sexuality Disability 1994; 12 (1): 53-79
67. Montorsi F, Guazzoni G, Rigatti P, et al. Pharmacological management of erectile dysfunction. Drugs 1995; 50 (3): 465-79
68. 1 and a combination of all three agents in the management of impotence. Int J Impot Res 1991; 3: 113-21
69. Floth A, Schramek P. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone. J Urol 1991 Jan; 145: 56-9
70. Shenfeld O, Hanani J, Shalhav A, et al. Papaverine-phentolamine and preostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol 1995; 154 (9): 1017-9
71. 1 with other intracavernous injections. Eur Urol 1994; 26 (4): 319-21
72. von Heyden B, Donatucci CF, Kaula N, et al. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J Urol 1993 May; 149 (5 Pt 2): 1288-90
73. Sweetser PM, Ravalli R, Brettschneider N, et al. A subjective comparison between the use of trimix, a combined 3-drug pharmacotherapy for impotence, and the use of papaverine/ regitine or prostagland E1 in 31 patients [abstract]. J Urol 1993 Apr; 149 Suppl.: 344A
74. de Almeida Claro J, Andrade E, Fregonesi A, et al. Treatment of impotence: the self-injection therapy with vasoactive drugs [in Portuguese]. Rev Bras Med 1994 Sep; 51: 1344-6
75. Hall S, Honig SC, Payton PR, et al. Use of atropine sulfate in pharmacolgic erections: initial experience with one year follow-up in the United States [abstract]. J Urol 1992; 147 Suppl. 4: 265A
76. Montorsi F, Guazzoni G, Bergamaschi F, et al. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence. Acta Diabetol 1994 Apr; 31: 1-5
77. Virag R, Shoukry K, Floresco J, et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. Urology 1991; 145: 287-93
78. 1 in erectile dysfunction. Efficiency and incidence of priapism. Br J Urol 1990 Jan; 65: 68-71
79. Hirsch IH, Smith RL, Chancellor MB, et al. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994 Oct; 32: 661-4
80. Adaikan PG, Ng SC, Chan C, et al. Why intracavernous PGE1 for diagnosis and treatment of impotence? Int J Impot Res 1990; 2 Suppl. 2: 325-6
81. Gerber GS, Levine LA. Pharmacological erection program using prostaglandin E1. J Urol 1991 Sep; 146: 786-9
82. Earle CM, Keogh EJ, Ker JK, et al. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury. Paraplegia 1992 Apr; 30: 273-6
83. Buvat J. The role of intracavernosal pharmacotherapy in the management of neurogenic and psychogenic impotence [abstract]. International Symposium on Basic and Clinical Pharmacotherapy of Penile Smooth Muscle; 1994; Madrid.
84. Giuliano F, Blanchet P, Banzet O, et al. Erectile dysfunction: effectiveness and tolerance of self-administered intracavernous alprostadil injections [in French]. Presse Med 1994 Oct 29; 23: 1516-21
85. Irwin MB, Kata EJ. High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994 Jan; 43: 84-7
86. Stackl W. Follow-up of patients on intracavernosal pharmacotherapy: frequency of visits, management of long-term complications, treatment compliance, drop-out rates. International Symposium on Basic and Clinical Pharmacotherapy of Penile Smooth Muscle 1994
87. McMahon CG. The return of spontaneous erections after self-injection of prostaglandin E1. Int J Impot Res 1992; 4: 179-86
88. 1] help restoring spontaneous erections [in French]. J Urol (Paris) 1993; 99 (3): 136-8
89. Katlowitz N, Albano GJT, Patsias G, et al. Effect of multidose intracorporeal injection and audiovisual sexual stimulation in vasculogenic impotence. Urology 1993 Dec; 42: 695-7
90. Katlowitz NM, Albano GJ, Morales P, et al. Potentiation of drug-induced erection with audiovisual sexual stimulation. Urology 1993 May; 41: 431-4
91. Donatucci CF, Lue TF. The combined intracavernous injection and stimulation test: diagnostic accuracy. Urology 1992; 148: 61-2
92. Nisen H. Cavernous auto-injeclion therapy with prostaglandin E1. Ann Chir Gynaecol 1993; 82 Suppl. 206: 69-73
93. Chandeck-Montesa K, Chen Jimenez J, Tamayo JC, et al. Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature [in Spanish]. Actas Urol Esp 1992 Mar; 16: 208-16
94. Weiske W-H. Long-term results in self-injection therapy (SIT) with PGE1 in 220 patients [abstract]. Int J Impot Res 1992; 4 Suppl. 2: A87
95. Pastorini S, Marino G, Cocimano V, et al. Complications of intracavernous pharmacologic infusion in impotence. Long-term results [in Italian]. Minerva Urol Nefrol 1993 Sep; 45: 109-12
96. Moriel EZ, Rajfer J. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol 1993 May; 149 (5 Pt 2): 1299-300
97. Jünnemann K-P, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1989; 1: 71-93
98. 1 for pharmacologic erection. J Urol 1989 Jun; 141: 1458-9
99. Chao R, Clowers DE. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction. Arch Phys Med Rehabil 1994 Mar; 75: 276-8
100. Montorsi F, Guazzoni G, Bergamaschi F, et al. Intracavernous vasoactive pharmacotherapy: the impact of a new self-injection device. J Urol 1993 Dec; 150: 1829-32
101. Chen J, Greenstein A, Kaver I, et al. Use of automatic insulin injector for intracorporeal injection in erectile dysfunction. J Urol 1994 Aug; 152: 461-2
102. Linet OI. Prostaglandins in erectile dysfunction. In: Vane JR, O'Grady J, editors. Therapeutic applications of prostaglandins. London: Edward Arnold, 1993: 105-21
103. Caverject® brand of alprostadil for injection data sheet. Upjohn, Kalamazoo, Michigan, USA. Jul 1995
104. Chen J, Godschalk MF, Katz G, et al. Incidence of penile pain after injection of a new formulation of prostaglandin E1. Urology 1995; 154: 77-9
105. Lewis RW. The pharmacologic erection. Probl Urol 1991; 5: 541-58
106. Schramek P, Plas EG, Hübner WA, et al. Intracavernous injection of prostaglandin E1 plus procaine in the treatment of erectile dysfunction. J Urol 1994 Oct; 152: 1108-10
107. McKay W, Morris R, Mushlin P. Sodium bicarbonate attenuates pain on skin infiltration with lidocaine, with or without epinephrine. Anesth Analg 1987; 66; 572
108. Keogh EJ. Absent cross-circulation between corpora cavernosa [letter]. J Urol 1989 Nov; 142: 1335
109. 1, Prostin VR Pediatric® Steril Solution) in patients with erectile dysfunction. Data on file, Upjohn, Kalamazoo, Michigan, USA. 1992
110. Lue TF, Hellstrom WJG, McAninch JW, et al. Priapism: a refined approach to diagnosis and treatment. J Urol 1986; 136: 104-8
111. Chen J, Godschalk M, Katz PG, et al. Peyronie's-like plaque after penile injection of prostaglandin E1. J Urol 1994 Sep; 152: 961-2
112. Lakin MM, Montague DK, Vanderburg Medendorp S, et al. Intracavernous injection therpy: analysis of results and complications. Urology 1990; 143 (6): 1138-41
113. Levine SB, Althof SE, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. Urology 1989; 141 (1): 54-7
114. 1) [abstract]. J Urol 1994; 151 Suppl. 5: 456A
115. Hirsch IH, Alexander A, Weitzel A, et al. Ultrasound monitoring of patients treated with chronic intracavernous prostaglandin E-1 [abstract]. J Urol 1993 Apr; 149 Suppl.: 344A
116. Caverject powder for injection data sheet. Upjohn Ltd., Crawley, West Sussex, UK. Jul 1995
117. Caverject: Riassunto delle caratteristiche del prodotto [in Italian]. Summary of product features. Upjohn S.p.A., Caponago, Milano. May 1995
118. Kaplan HS. The combined use of sex therapy and intrapenile injections in the treatment of impotence. J Sex Marital Ther 1990 Win; 16: 195-207
119. Gregoire A. New treatments for erectile impotence. Br J Psychiatry 1992; 160: 315-26
120. Higgins G. Muse® device for erectile dysfunction. Inpharma 1995; Jul 1: 3-4
121. Chen J, Godschalk MF, Katz G, et al. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction. J Urol 1995; 153: 1476-7
122. Knispel HH. Penile venous surgery in impotence: results in highly selected cases. Urol Int 1991; 47: 144-8
123. Allen RP, Engel RM, Smolev JK, et al. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1. J Urol 1992 Oct; 148: 1181-3